🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Jiangsu vcare pharmaceutical technology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Jiangsu vcare pharmaceutical technology as lead sponsor. Synced 27 Sep 2026
12Current trials
8Recruiting now
4Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Jiangsu vcare pharmaceutical technology is the lead sponsor of 12 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are VC005, VC004 and VC005 group. The most-studied condition is Atopic Dermatitis.

ClinicalTrials.gov trials by status

  • Recruiting867%
  • Not yet open433%

Trials by phase

  • Phase 3542%
  • Phase 2325%
  • Phase 1325%
  • Phase 1/218%
01

Clinical trials sponsored by Jiangsu vcare pharmaceutical technology

12 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
NCT07598383 · ClinicalTrials.gov ↗ · Atopic Dermatitis
Phase 2 Recruiting 2026-06 China
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
NCT07172347 · ClinicalTrials.gov ↗ · Non-segmental Vitiligo
Drug: VC005
Phase 2 Recruiting 2025-10 China
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
NCT07172360 · ClinicalTrials.gov ↗ · Active Ankylosing Spondylitis
Drug: VC005
Phase 3 Recruiting 2025-12 China
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
NCT07749716 · ClinicalTrials.gov ↗ · Alopecia Areata
Drug: VC005
Phase 2 Recruiting 2026-08 China
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
NCT06577519 · ClinicalTrials.gov ↗ · Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Phase 3 Recruiting 2024-09 China
Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
NCT07592585 · ClinicalTrials.gov ↗ · Atopic Dermatitis
Drug: VC005
Phase 3 Recruiting 2026-05 China
Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors
NCT06658353 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumor
Drug: VC004
Phase 3 Recruiting 2025-03 China
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
NCT06723080 · ClinicalTrials.gov ↗ · Moderate to Severe Atopic Dermatitis
Phase 3 Recruiting 2024-12 China
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
NCT07828639 · ClinicalTrials.gov ↗ · Non-Segmental Vitiligo
Drug: VC005
Phase 1/2 Not yet open 2026-09 China
Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects
NCT07796191 · ClinicalTrials.gov ↗ · Healthy Adult Participants
Phase 1 Not yet open 2026-09 China
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
NCT07762443 · ClinicalTrials.gov ↗ · Alopecia Areata
Drug: VC005
Phase 1 Not yet open 2026-09 China
A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone Metastases
NCT07731685 · ClinicalTrials.gov ↗ · Pain in Bone Metastases
Drug: VC004
Phase 1 Not yet open 2026-07 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Jiangsu vcare pharmaceutical technology trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Jiangsu vcare pharmaceutical technology trials

10 conditions
Atopic Dermatitis2Alopecia Areata2Non-Segmental Vitiligo1Non-segmental Vitiligo1Active Ankylosing Spondylitis1Healthy Adult Participants1Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)1Locally Advanced Solid Tumor1Moderate to Severe Atopic Dermatitis1Pain in Bone Metastases1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China128

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Atopic Dermatitis

SponsorTrials
Innovent Biologics (Suzhou)4
Keymed Biosciences4
Apogee Therapeutics3
Inmagene2
Target PharmaSolutions2
Bambusa Therapeutics2
University Hospital Schleswig-Holstein2
LEO Pharma1
Kymera Therapeutics1
Galderma R&D1

Sponsors with the most current trials registered for this condition.

06

Questions about Jiangsu vcare pharmaceutical technology trials

How many clinical trials does Jiangsu vcare pharmaceutical technology sponsor?

Jiangsu vcare pharmaceutical technology is the lead sponsor of 12 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Jiangsu vcare pharmaceutical technology trials recruiting?

Yes. 8 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jiangsu vcare pharmaceutical technology testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are VC005 (6), VC004 (2), VC005 group (2) and Clopidogrel (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.